The 60,000 IU weekly sachet: a uniquely Indian problem.

The bottom line first

The deficiency is real — and severe

India has one of the highest rates of vitamin D deficiency in the world, despite being a tropical country. The paradox is explained by behaviour: urban Indians spend most daylight hours indoors, skin melanin density reduces cutaneous synthesis, and vegetarian diets provide almost no dietary vitamin D.

A 2019 AIIMS study across four Indian cities found approximately 40% of children and 70% of adults had 25(OH)D levels below 20 ng/mL — a level most endocrinologists consider deficient.¹ Delhi and Mumbai indoor office workers average 10–14 ng/mL — a range associated with secondary hyperparathyroidism and impaired calcium absorption over time.

Where the 60,000 IU sachet came from

The sachet format emerged from a practical problem in the 1990s: India needed a scalable way to treat a population with high deficiency rates, limited access to regular follow-up, and poor daily-tablet compliance. A once-weekly sachet dissolved in water is operationally simple. Physicians could hand patients eight sachets and send them home for two months — no daily habit required.

This was reasonable public health logic. The problem is that it was designed for treatment, not maintenance — and it has drifted into maintenance use because the format is convenient and prescribing culture hasn't caught up.

The serum response problem

Vitamin D is fat-soluble and stored in adipose and hepatic tissue, released slowly. Very large single doses create a pharmacokinetic spike followed by a trough — not a stable plateau. Tripkovic et al. (2017) compared weekly bolus vs daily supplementation and found daily dosing produced a significantly higher and more stable serum 25(OH)D plateau than equivalent total-dose weekly bolus supplementation.²

What the 2025 ICMR revision actually changed

Target range revised upward. The 2020 ICMR position recommended maintaining 25(OH)D above 20 ng/mL. The 2025 revision raises the target to 30–60 ng/mL — aligning India with the Endocrine Society's global recommendation, and acknowledging that "sufficient" at 20 ng/mL underserves a population with widespread secondary hyperparathyroidism.

Daily low-dose supplementation now explicitly mentioned for maintenance. The 2025 document distinguishes between repletion (where the 60,000 IU sachet protocol remains acceptable) and maintenance (where 1,000–2,000 IU/day is preferred for otherwise-healthy adults). This distinction was absent in previous ICMR guidance.

Testing before supplementation recommended. The revision states individuals should ideally confirm deficiency by 25(OH)D serum test before beginning supplementation — a change from previous guidance that implicitly endorsed presumptive supplementation.

When the sachet is still the right tool

The sachet has legitimate clinical indications. We are arguing against its misuse as a maintenance supplement, not against its existence. The protocol — 60,000 IU weekly for 8 weeks — is appropriate for confirmed severe deficiency (<12 ng/mL), particularly in patients with malabsorption issues, poor daily compliance, or physician management with a follow-up retest.

The daily alternative

1,000–2,000 IU/day of cholecalciferol (D3) in an oil-based softgel produces a stable plateau of approximately 28–40 ng/mL in most deficient Indian adults over 10–12 weeks, depending on baseline and body weight.⁴

Reader action